Parents’ Information Needs in Tumor Necrosis Factor-α Inhibitor Treatment Decisions

2013 ◽  
Vol 56 (3) ◽  
pp. 244-250 ◽  
Author(s):  
Ellen A. Lipstein ◽  
Daniel J. Lovell ◽  
Lee A. Denson ◽  
David W. Moser ◽  
Shehzad A. Saeed ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Information Needs ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Treatment Decisions ◽  
Factor Α ◽  
Necrosis Factor ◽  
Inhibitor Treatment

scholarly journals Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor Treatment

2016 ◽  
Vol 55 (19) ◽  
pp. 2877-2880 ◽  
Author(s):  
Takahiro Takazono ◽  
Toyomitsu Sawai ◽  
Masato Tashiro ◽  
Tomomi Saijo ◽  
Kazuko Yamamoto ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Pulmonary Cryptococcosis ◽  
Factor Α ◽  
Necrosis Factor ◽  
Inhibitor Treatment

scholarly journals Serum anti-Müllerian hormone levels in women with rheumatoid arthritis during tumor necrosis factor-α inhibitor treatment: Exploratory research

2019 ◽  
Vol 12 (4) ◽  
pp. 186-189 ◽  
Author(s):  
Sakiko Isojima ◽  
Yoko Miura ◽  
Mayu Saito ◽  
Nobuyuki Yajima ◽  
Yusuke Miwa ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Premenopausal Women ◽  
Exploratory Research ◽  
Hormone Levels ◽  
Factor Α ◽  
Necrosis Factor ◽  
Inhibitor Treatment

Background We evaluated serum anti-Müllerian hormone in women with rheumatoid arthritis newly introduced to tumor necrosis factor-α inhibitor treatment for 54 weeks to investigate the treatment’s effect on ovarian reserve. Methods A total of 12 premenopausal women with rheumatoid arthritis aged 20–50 years were recruited at our division, who had been newly treated with tumor necrosis factor-α inhibitor (infliximab or etanercept) from 1 April 2008 to 31 March 2014. Serial serum anti-Müllerian hormone levels and disease activity scores (DAS28-CRP) were examined at defined periods: start of treatment and 14, 30, and 54 weeks after start of treatment. Results DAS28-CRP scores in 12 women were significantly decreased from a mean of 4.6 (±SD: 0.4) to 2.3 (±0.4) after 54 weeks of treatment ( p < 0.001). Serum anti-Müllerian hormone levels and its z scores did not change significantly. Conclusion Treatment with a tumor necrosis factor-α inhibitor did not affect serum anti-Müllerian hormone levels in 12 women with rheumatoid arthritis during 54-week treatment.

Sign in / Sign up

Export Citation Format

Share Document